THE RARE ACCESS ACTION PROJECT (RAAP) is a non-profit (501 c4) organization whose membership consists of patient advocates, emerging life science companies, and other rare disease stakeholders advocating for innovative solutions to reduce or eliminate barriers to rare therapies.
Chairman of the Board
Michael is a 25-plus year veteran of the life sciences, having led government affairs, public policy, and advocacy teams both in the U.S. and globally. Recently, he served as Vice President of Global Government Affairs and Advocacy at Novelion, as the company transitioned prior to being acquired by Amryt. He was responsible for market access-oriented government affairs and advocacy development in support of launches in Europe, South America and Japan.
While he has spent a number of years in larger global companies, he transitioned to the emerging life sciences where he led efforts in patient services, market access, payer strategies, product focused government affairs, and patient-oriented advocacy. Currently, Michael is a partner at Acuity Strategic partners where he has a practice that encompasses the life sciences, as well as the diagnostics and broader healthcare industry. In addition, Michael is a partner at Bridgewater Partners where he works with companies to develop compliant sales and marketing initiatives. Beginning in 2016, Michael also formed and leads a coalition of emerging, mid to large cap, and pre-market rare diseases companies and patient advocates known as the Rare Access Action Project. There he serves as the Executive Director with a focus on providing State and Federal solutions to enhance patient access to rare disease therapies.